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Using an adjuvant-induced arthritis rat model, we investigated the effects of a lipid extract of
Perna canaliculus (Lyprinol) on pain. Radiological examinations, as well as levels of pro- and
anti-inflammatory (AI) cytokines, were measured aiming to provide independent objective data
to the pain controlling investigation. We confirmed the ability of Lyprinol to control pain at
the initial phase of its administration; with similar efficacy to that observed with Naproxen. The
pain scores slowly increased again in the group of rats treated with Lyprinol after day 9–14.
The Naproxen-treated rats remained pain-free while treated. Both Naproxen and Lyprinol
decreased the levels of the pro-inflammatory cytokines TNF-a and IFN-g, and increased that of
IL-10. Extra-virgin olive oil was ineffective on cytokine secretion. Rats treated with Lyprinol
were apparently cured after 1 year. This study confirms the AI efficacy of this lipid extract of P.
canaliculus, its initial analgesic effect, its perfect tolerance and its long-term healing properties.
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Introduction
Lipid Extract of New Zealand Green-lipped Mussel
(Lyprinol)
A lipid-rich and stabilized extract of New Zealand green-
lipped mussel Perna canaliculus powder (NZGLM,
Lyprinol), has been shown to have significant anti-
inflammatory (AI) activity when given to animals and
humans (1–11). This article contributes to the emerging
literature on bioprospecting (12). This approach seeks to
emphasize for complementary and alternative medicine
(CAM) the utility of products derived from animals in
treating certain diseases (13–17). Lyprinol is a mixture
of five main lipid classes including sterol esters, triglycer-
ides, free fatty acids, sterols and polar lipids (18,19).
There are 90 component fatty acids in Lyprinol (18,19).
Omega-3 polyunsaturated fatty acids are one of the most
abundant PUFAs. Eicosapentaenoic acid (20 carbons
and 5 double bonds, shorthand=20 : 5 omega-3) (EPA)
and docosahexaenoic acid (22 : 6 omega-3) (DHA) are
the major omega-3 PUFAs present in Lyprinol.
Anti-inflammatory Effects
Although the exact active ingredients that brought
about this AI effect are unknown, Whitehouse et al. (3)
reported that Wistar and Dark Agouti rats treated p.o.
with this lipid extract did not develop adjuvant-induced
polyarthritis or collagen (II)-induced auto-allergic arthri-
tis. This was achieved with doses inferior to the ones
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of NSAIDs, and 200 times lower than other seed or fish
oils (3). Further, omega-3 PUFA subfractions of this
lipid extract inhibited LTB4 biosynthesis by neutrophils
in vitro, and PGE2 production by activated macrophages
(20). Subfractions of this extract containing natural
antioxidants (e.g. carotenoids) also exhibited AI activity
(5). In contrast to NSAIDs, Lyprinol is non-gastro-toxic
in disease-stressed rats at 300mgkg1 p.o. (3), and does
not affect platelet aggregation in both humans and
rats (3).
Clinical studies, either controlled or randomized, have
demonstrated that Lyprinol has highly significant AI
activity in patients with osteoarthritis (OA) (4,7,8,21),
asthma (22) and other inflammatory conditions (10).
Therefore, it seems that Lyprinol is a reproducible,
stable source of bioactive lipids with much greater
potency than plant/marine oils currently used as nutri-
tional supplements to ameliorate signs of inflammation
(3,10,23). More importantly, in humans and animal
subjects taking Lyprinol, there are no reported side-
effects, even at doses up to 2500mg per day in patients.
Given the AI activities of Lyprinol, we were interested
to know if these AI effects could be translated into pain-
controlling effects. We conducted a series of experiments
to understand the AI mechanism of action of this
lipid extract. This article reports our findings on the
pain scores and the accepted causes of pain in rats
subjected to severe arthritis induced by adjuvant. In
comparison to extra-virgin olive oil (vehicle/negative
control) and to the NSAID Naproxen (positive control),
we confirmed the pain-controlling ability of Lyprinol at
the initial phase of its administration. This ability is
similar to the one observed with Naproxen. Cytokine
levels in/from splenocytes of these animals, as well as
radiological examination of the affected joints, were also
measured to bring objective confirmation to the pain
controlling investigation.
Methods
Chemicals
Unless stated otherwise, all chemicals were purchased
from Sigma (St Louis, MO, USA). All chemicals were at
least of AR grade. Organic solvents used were at least
of HPLC grade.
Induction of Inflammation in Sprague-Dawley Rats
Four groups of six 6-week-old male Sprague-
Dawley (SD) rats (normal group, adjuvant-induced
arthritis (AIA) group, AIA+Naproxen group and
AIA+Lyprinol group) and two groups of three 6-week
old SD rats (AIA group and AIA+ long-term Lyprinol
feeding group, respectively) were purchased from the
Central Animal Facility (CAF) of Hong Kong
Polytechnic University (HKPU). All rats were kept and
cared under conditions that fully met requirements
of Procedures for the Care of Laboratory Animals
or Animals (Control of Experiments) Regulations
Chapter 340 of the Hong Kong SAR government.
Ethics approval (ASESC No.04/9) was from The
Animal Subjects Ethics subcommittee of the HKPU.
Arthritis was induced in anesthetized rats by administra-
tion of adjuvant according to a method previously
described (24,25). Briefly, on Day 0, each rat was injected
into the paw of the right hind limb with 100 ml
of Freund’s complete adjuvant containing 10mgml1 of
Mycobacterium butyricum (Difco, Livonia, MI, USA).
Another six rats without arthritis induction were
observed as a normal group.
Products/Drug Tested Fed to the Treatment
and Control Groups of Rats
Rats in the Lyprinol (Pharmalink International Ltd,
Burleigh Heads, QLD, Australia) group were fed by oral
gavage at a dosage of 25mg Lyprinol kg1 body weight.
Typically, the required amount of Lyprinol was made up
with olive oil (Virgin, Bertolli, Italy) to 300 ml and then
force-fed to the rats with a stainless steel stomach tube.
Three hundred micro liters of olive oil, and 20mgkg1
body weight of Naproxen were fed as vehicle and positive
control. Normal chow was provided to all rats. Except
for the long-term Lyprinol-feeding group, feeding of
Lyprinol, olive oil and Naproxen were discontinued after
the experimental period of 28 days. For the long-term
Lyprinol-feeding group, the required amount of diluted
Lyprinol (to a dosage of 25mgkg1 body weight) was
added onto 25 g of dry rat chow. These chows were fed to
rats daily. Once these chows were completely consumed,
normal chows were given.
Pain Score Measurement
The measurement of pain score was performed according
to Hayashida et al. (26). The number of pain-related
responses, represented by vocalizations, was recorded
during 10 flexions of the tarsotibial joints of the
adjuvant-injected paw. Results were expressed as the
mean number of vocalizations.
Splenocyte Preparation
At Day 14 and 28 after arthritis induction, splenocytes of
each rat of group P. canaliculus, Naproxen, olive oil and
control were prepared as described previously (27).
Briefly, spleens were removed aseptically and minced
into tiny pieces. Single cell suspensions were prepared
by gentle grinding of spleen pieces in RPMI 1640 medium
(Life Technologies, US). Splenocytes (mostly B- and
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T-cells) from the crude spleen cell suspension were
recovered by using Ficoll-Hypaque Plus lymphocyte
isolation kit (Pharmacia Biotech, USA) as described in
the manufacturer’s manual. Recovered splenocytes
(1.5ml) were transferred into a sterile centrifuge tube
and four volumes of pre-chilled 0.83% ammonium
chloride (NH4Cl) was added and incubated for 10min
for lysis of residual erythrocytes (28). Splenocytes were
recovered by centrifugation at 3000 rpm for 5min,
washed with 8ml pre-warmed (37C) sterile PBS buffer
(137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO47H2O,
1.4mM KH2PO4, pH 7.4) and finally resuspended in
appropriate volume of complete RPMI 1640 medium
(10% fetal bovine serum, 100 units ml1 of penicillin
and 100 mgml1 of streptomycin, supplemented with
0.3 mg/ml L-glutamine and 25mM HEPES).
Cell Count and Viability Staining
Resuspended splenocytes were stained with 0.4% Trypan
blue exclusion dye (0.4 g Trypan blue in 100ml PBS
buffer) at ratio 1: 1. Number of splenocytes was counted
and calculated with the aid of a hemocytometer. More
than 99% of splenocytes were viable. Except stated
otherwise, splenocytes were diluted to a working popula-
tion of 5 106 cells ml1 in all experiments.
ELISA Assay for Cytokines
A total of 5 106 splenocytes ml1 were seeded in 24-well
plate; a suboptimal concentration (1.25 mgml1) of
lipopolysaccharide (LPS) (Sigma, St Louis, MO, USA)
was used to prime the splenocyte culture. Splenocytes
were incubated in 37C incubator with 80% humidity
and 5% CO2 atmosphere condition. Supernatant was
collected at 10 and 24 h after LPS activation and stored
at 80C until later measurement. Interleukin-10 (IL-10),
tumor necrosis factor-alpha (TNF-a) and interferon-
gamma (IFN-g) were measured by enzyme-liked immuno-
sorbent assay (ELISA) (BioSource, CA, USA) as
described in the user’s manual.
Statistical Analysis
Experimental data were compared to the ones of the
control group and analyzed by Student’s t-test with one
way ANOVA.
Results
Photographic and Radiographic Analysis of AIA Rat Paws
Figure 1 shows photographs of the right hind paw of rat
at different times after AIA induction. Figure 1A was
taken at 14 days after AIA induction. Swelling of the
whole right hind paw, especially around the tarsotibial
joints, is significant as shown in the photo. X-ray
photography of the same paw at Day 21 after AIA
reveals severe periarticular soft tissue swelling, joint
subluxation and periostal new bone formation (Fig. 1B).
The degree of arthritis between control group and
Lyprinol group shows no difference during the whole
28-day course of the experiment. However, 1 year after
the induction of AIA, deformation of joints and lesions
are still observable in the olive oil-control group
(Fig. 1C). Conversely, deformation of joints and lesions
are not visible in the Lyprinol-long-term treatment
group (Fig. 1D).
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Figure 1. Photographic and radiographic analysis of adjuvant-induced
arthritis (AIA) rats. (A) Photograph of the right hind paw taken
14 days after AIA induction. Swelling and inflammation of the paws
were observed, especially around the ankle region. (B) Radiographic
analysis of the same right hind paw at Day 21 after AIA induction.
Note the swelling of soft tissues as well as bone deformation around the
ankle region. (C) Photograph of the right hind paw in one of the
representative rats in the olive oil group at 1 year after AIA induction.
Toes and footpad are deformed, with multiple lesions. (D) However,
rats fed with Lyprinol-for 1 year recovered much better. Photograph
of the right hind paw in one of the representative rats in the Lyprinol
treatment group showed only mild joint deformation and no lesion.
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Pain Score Measurement
Pain score measurement is a widely used and reliable
method to reflect the effectiveness of different treatments
on AIA (26). It is one of the commonly used
methodologies to measure level of pain (29,30,31).
As shown in Fig. 2, the NSAID Naproxen effectively
maintained the pain score of AIA rats at a relatively low
level during the whole course of the experiment.
Compared to the ones of the control and olive oil-
treated groups, Lyprinol effectively lowered the pain
score of AIA rats from Day 4 to Day 26 after induction
of arthritis. The effect of Lyprinol was most pro-
nounced between Day 4 and Day 12, with an effect
comparable to that of Naproxen. The effect of Lyprinol
began to wane after Day 14, but still maintained the
pain score at a significantly lowered level when compared
to the control and olive oil-treated groups. Our results
clearly demonstrated that Lyprinol is very useful in
controlling pain of severe arthritis, especially during the
early and intermediate phase of AIA.
Level of Pro-inflammatory Cytokines Tumor Necrosis
Factor-alpha and interferon-gamma
At Day 14 after induction of arthritis, splenocytes from
Lyprinol-fed rats were harvested and pro-inflammation
cytokines levels were determined. As shown in Fig. 3,
TNF-a level of Lyprinol group was greatly decreased
from 3.07 0.168 to 1.71 0.405 ngml1. Besides,
production of another pro-inflammatory cytokine,
IFN-g, was significantly decreased. As shown in Fig. 4,
the IFN-g level of the Lyprinol group, when compared
to control, was dramatically decreased from level
10.7 0.8 to 3.0 0.9 ngml1.
Level of Anti-inflammatory Cytokine Interleukin-10
Figure 5 shows that the AI cytokine IL-10 increased at
Day 28 after AIA. Although there is no statistically
significant difference between the levels observed in the
control group and the Lyprinol group, the increase of
IL-10 in the Lyprinol group almost reached levels
observed in the positive control group (Naproxen).
Discussion
Pain score measurement is a widely used and reliable
method to reflect the effectiveness of different treatments
on AIA (26). It is one of the commonly used methodol-
ogies to measure level of pain. AIA in the rat is a
standard model accepted for the study of inflammation
and its control by medications or supplements (32).
We used this model in order to get a better understanding
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Figure 2. Mean pain score measured by 10 flexions of the tarsotibial
joints of adjuvant-injected paw (n=6), as described in Methods.
Note that Lyprinol effectively controlled pain between Day 4 and
Day 12 when compared to control and olive oil groups.
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Figure 3. Amount of tumor necrosis factor-alpha (TNF-a) produced by
LPS-stimulated splenocytes 14 days after arthritis induction. Lyprinol
controlled the amount of TNF-a production to a level similar to the
one found in rats with no arthritis, and was as effective as the NSAID
Naproxen. Values shown here are mean SEM (n=6). *P<0.05.
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Figure 4. Amount of interferon-gamma (IFN-g) produced by
LPS-stimulated splenocytes 14 days after arthritis induction.
Lyprinol effectively reduced the amount of IFN-g produced, when
compared to control and olive oil groups. Strikingly, Lyprinol was
even more potent than the NSAID Naproxen in controlling the IFN-g
level. Values shown are mean SEM (n=6). *P<0.05; **P<0.001.
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of mechanisms resulting in AI effects of the lipid extract
of P. canaliculus, the green-lipped mussel from New
Zealand (Lyprinol). A number of studies have been
reported and/or published on this product in terms of its
composition, its effects when compared with other drugs
or lipids of diverse origins, its efficacy in several animal
models and its effects on symptoms of OA and asthma.
Since the major complaint of patients suffering from
acute exacerbations of chronic inflammatory disease is
pain, we evaluated the analgesic effect of the lipid extract
in the AIA rat model. We also measured levels of pro-
inflammatory and anti-inflammatory cytokines. We
compared results observed of Lyprinol, with a sham
group (no drugs), an olive oil group (negative control), a
non-steroid AI drug (NSAID) and a Naproxen (positive
control) group. We also observed a group of rats
as reference that were not treated with adjuvant.
Recent studies on pain, both in humans (33–36) and
animals (34,37,38) have demonstrated the active role
of IL-6 in inducing pain, as well as IL-1b, IL-8, TNF-a
(TNF-R1 receptor) and IFN-g. Conversely, IL-10 is
associated with control of pain.
Lyprinol exhibits a significant effect controlling pain
in several recent clinical studies. The group at the
University of Hong Kong (8) conducted the first
randomized controlled trial to evaluate the effects of
Lyprinol, on signs and symptoms and quality of life
(QOL) of patients with knee OA. Their results showed
that Lyprinol over 6 months in patients with knee OA is
perfectly tolerated and associated with a decrease in pain
perception after 2 months when compared to placebo.
The visual analog scale (VAS) for pain score was
significantly reduced from 63.0 at baseline to 55.5 at
Week 4 (P=0.046), 51.2 at Week 8 (P=0.003) and
49.7 at Week 12 (P=0.001). There was a greater
significant reduction in VAS pain score following
adjustment for change in amounts of paracetamol
(acetaminophen) used in patients who received the lipid
extract when compared with controls at Week 8
(P=0.035), Week 12 (P=0.032) and Week 24
(P=0.045).
Another multi-center clinical study in Korea on patients
with OA of the hip and knee found that the average VAS
score, Lequesne functional index, global assessment by
patients and global assessment by physician were all
significantly improved (7). After a 4- and 8-week treatment
period, 53–80% of patients experienced significant pain
relief, and improvement of joint function. There was no
reported adverse effect during this clinical trial (7).
A third study was conducted in Germany on 50 adults
with inflammatory rheumatoid arthritis (21). The number
of painful joints was reduced from 4.18 2.80 at baseline
by 0.30 0.81 points (7.2%) after 6 weeks and
0.60 1.18 points (14.4%) after 12 weeks (P=0.012
and P=0.001). For a sub-parameter ‘number of painful
small joints’, a highly significant reduction of 9.3%
after 6 weeks and 18.6% after 12 weeks was observed
(P=0.022 and P=0.002). Analgesic medications were
reduced or stopped in 21 subjects who required these
at the beginning of the trial.
Our study of the mean pain score measurement by
ten flexions of the tarsotibial joints of adjuvant-injected
paw (n=6) did demonstrate a significant reduction of pain
in AIA rats treated with Lyprinol, or Naproxen. However,
this reduction differed according to the product used to
treat the rats: pain scores in Naproxen and Lyprinol
groups initially increased; but they decreased significantly
and gradually in the Lyprinol group to reach a nadir
(score=2) at Day 8, while rats in the Naproxen group
experienced a more erratic pain reduction with a significant
nadir (score=0) at Day 9. However, the pain score started
differing significantly after Day 9: the Lyprinol group
experienced a progressive increase in pain scores, reaching
its initial level at Day 15; while the Naproxen group
remained essentially pain-free during the rest (total
days=26) of the experiment. This curve, transposed to
the human time scale, is quasi-identical to the pain scale
observed by Lau et al. (8) where the maximum reduction in
pain was observed after approximately 8–12 weeks of
treatment in patients with OA. It may well be due to an
‘escape’ mechanism from the production of pro-inflamma-
tory cytokines that tend to increase despite treatment with
Lyprinol; it may also be due to other inflammatory
mechanisms of AIA (and/or OA).
The cause of pain severity was confirmed by aspects of
the inflamed paw when compared with the non-injected
one, and comparative radiological images. X-rays con-
firmed the presence of major osteo-cartilaginous destruc-
tion as well as major swelling of the affected paw.
Pro-inflammatory cytokine production (TNF-a, IFN-g)
was significantly controlled by Lyprinol (Day 14), as well
if not better than Naproxen. IL-10, an ‘anti-inflammatory’
cytokine was increased in the Lyprinol and in the
Naproxen group, but did not reach statistical significance.
Extra-virgin olive oil was ineffective in our study.
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Figure 5. Amount of interleukin-10 (IL-10) produced by LPS-stimulated
splenocytes after 28 days of arthritis induction. Lyprinol can increase
the amount of IL-10 production, an anti-inflammatory cytokine,
although the difference was not statistically significant. Values shown
are mean SEM (n=6).
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More importantly, after 1 year, rats that were treated with
Lyprinol had a normal AIA paw, while untreated rats had
severe inflammatory, ulcerative lesions.
Conclusion
The lipid extract of P. canaliculus is known as a powerful
AI product in animal models and human diseases
(asthma, arthritis). We have confirmed in the adjuvant-
induced arthritis rat model, that this product (Lyprinol)
is an analgesic, as active as Naproxen during the early
phase of treatment. AIA is a loco-regional highly
inflammatory experimental condition, with systemic
repercussions. Lyprinol also controls as well as
Naproxen the levels of pro-inflammatory cytokines
(TNF-a, IFN-g) in AIA rats; it increases the production
of the AI cytokine IL-10 in AIA rats. Lyprinol was
perfectly tolerated, and AIA rats treated with Lyprinol
were lesion-free after 1 year, while untreated controls had
major inflammatory, ulcerative lesions. The lipid extract
of P. canaliculus seems to be uniquely safe and effective
in the treatment of pain, both spontaneous (due to
inflammation) and triggered by torsion of the affected
joint, in AIA in rats.
Acknowledgements
Prof. Georges M. Halpern (MD, PhD) initiated this
study; organized it and helped to shape the manuscript.
He should have been the leading author. We thank
Pharmalink International Company Ltd, Burleigh Heads,
QLD, Australia, for supplying the lipid extract of
P. canaliculus (Lyprinol) and the placebo, and for an
unrestricted educational and research grant that sup-
ported our study in part.
References
1. Gibson RG, Gibson SLM, Conway V, Chappell D. Perna
canaliculus in the treatment of arthritis. Practitioner 1980;224:955–
60.
2. Speed A, Zwar D. Introducing: the Ocean mussel that packs a
punch against arthritis pain. Bio/Tech News 1997.
3. Whitehouse MW, Macrides TA, Kalafatis N. Anti-inflammatory
activity of a lipid fraction (Lyprinol) from the N. Z. green-lipped
mussel. Inflammopharmacology 1997;5:237–46.
4. Gibson SLM, Gibson RG. The treatment of arthritis with a lipid
extract of Perna canaliculus: a randomized trial. Complement Ther
Med 1998;6:122–6.
5. Halpern GM. Anti-inflammatory effects of a stabilized lipid extract
of Perna canaliculus (Lyprinol). Allergie Immunol (Paris)
2000;32:272–8.
6. Shiels IA, Whitehouse MW. Lyprinol: anti-inflammatory and
uterine relaxant activities in rats, with special reference to a model
for dysmenorrhea. Allergie Immunol (Paris) 2000;32:279–83.
7. Cho SH, Jung YB, Seong SC, Park HB, Byun KY, Lee DC, et al.
Clinical efficacy and safety of Lyprinol, a patented extract from
New Zealand green-lipped mussel (Perna canaliculus) in patients
with osteoarthritis of the hip and knee: a multicenter 2-month
clinical trial. Allergie Immunol (Paris) 2003;35:212–6.
8. Lau CS, Chiu PKY, Chu EMY, Cheng IYW, Tang WM,
Man RYK, et al. Treatment of knee osteoarthritis with
Lyprinol, lipid extract of the green-lipped mussel -a double-blind
placebo-controlled study. Prog Nutrition 2004;6:17–31.
9. Tenikoff D, Murphy KJ, Le M, Butler RN, Howarth GS,
Howe PR. LyprinolTM: a potential preventive treatment for
inflammatory bowel disease (IBD). Asia Pac J Clin Nutr 2004;13
(Suppl): S94.
10. Halpern GM. The Inflammation Revolution. Garden City, NY,
USA: Square One Publishers, 2005.
11. Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS. Lyprinol
(stabilized lipid extract of New Zealand green-lipped mussel):
a potential preventative treatment modality for inflammatory
bowel disease. J Gastroenterol 2005;40:361–5.
12. Cooper EL. Bioprospecting a CAM frontier. Evid Based
Complement Alternat Med 2005;2:1–3.
13. Balamurugan M, Parthasarathi K, Cooper EL, Ranganathan LS.
Earthworm paste (Lampito mauritii, Kinberg) alters inflammatory,
oxidative, haematological and serum biochemical indices of
inflamed rat. Eur Rev Med Pharmacol Sci 2007;11:77–90.
14. Prakash M, Balamurugan M, Parthasarathi K, Gunasekaran G,
Cooper EL, Ranganathan LS. Anti-ulceral and anti-oxidative
properties of ‘‘earthworm paste’’ of Lampito mauritii (Kinberg) on
Rattus norvegicus. Eur Rev Med Pharmacol Sci 2007;11:9–15.
15. Suzuki KM, Isohama Y, Maruyama H, Yamada Y, Narita Y, Ohta
S, et al. Estrogenic activities of fatty acids and a sterol isolated from
royal jelly. Evid Based Complement Alternat Med. doi:10.1093/ecam/
nem036.
16. Nigam Y, Bexfield A, Thomas S, Ratcliffe NA. Maggot therapy:
the science and implication for CAM Part I—history and
bacterial resistance. Evid Based Complement Alternat Med
2006;3:223–7.
17. Nigam Y, Bexfield A, Thomas S, Ratcliffe NA. Maggot
therapy: the science and implication for CAM Part II—maggots
combat infection. Evid Based Complement Alternat Med
2006;3:303–8.
18. Murphy KJ, Mooney BD, Mann NJ, Nichols PD, Sinclair AJ.
Lipid, FA, and sterol composition of New Zealand green-lipped
mussel (Perna canaliculus) and Tasmanian blue mussel (Mytilus
edulis). Lipids 2002;37:587–95.
19. Wolyniak CJ, Brenna T, Murphy KJ, Sinclair AJ. Gas chromato-
graphy-chemical ionization-mass spectrometric fatty acid analysis
of a commercial supercritical carbon dioxide lipid extract from
New Zealand green-lipped mussel (Perna canaliculus). Lipids
2005;40:355–60.
20. Dugas B. Lyprinol inhibits LTB4 production by human monocytes.
Allergie Immunol (Paris) 2000;32:284–9.
21. Gruenwald J, Graubaum HJ, Hansen K, Grube B. Efficacy and
tolerability of a combination of Lyprinol and high concentrations
of EPA and DHA in inflammatory rheumatoid disorders. Adv Ther
2004;21:197–201.
22. Emelyanov A, Fedoseev G, Krasnoschekova O, Abulimity A,
Trendeleva T, Barnes PJ. Treatment of asthma with lipid extract
of New Zealand green-lipped mussel: a randomised clinical trial.
Eur Respir J 2002;20:596–600.
23. Murphy KJ, Mann NJ, Sinclair AJ. Fatty acid and sterol
composition of frozen and freeze-dried New Zealand Green
Lipped Mussel (Perna canaliculus) from three sites in New
Zealand. Asia Pac J Clin Nutr 2003;12:50–60.
24. Kang SS, Choi SH. Prophylactic effect of plaster and cataplasm
contained ketoprofen in rats with adjuvant arthritis. J Vet Sci
2001;20:65–70.
25. Winder CV, Lembke LA, Stephens MD. Comparative bioassay of
drugs in adjuvant-induced arthritis in rats: flufenamic acid,
mefenamic acid, and phenylbutazone. Arthritis Rheum
1969;12:472–82.
26. Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Ando K,
Harada E. Oral administration of lactoferrin inhibits inflammation
and nociception in rat adjuvant-induced arthritis. J Vet Med Sci
2004;66:149–54.
27. Nakaya M, Yamasaki M, Miyazaki Y, Tachibana H, Yamada K.
Estrogenic compounds suppressed interferon-gamma production in
mouse splenocytes through direct cell-cell interaction. In Vitro Cell
Dev Biol Anim 2003;39:383–7.
28. Zimecki M, Weber-Dabrowska B, Lusiak-Szelachowska M,
Mulczyk M, Boratynski J, Pozniak G, et al. Bacteriophages provide
244 Pain controlling and cytokine-regulating effects of Lyprinol
regulatory signals in mitogen-induced murine splenocyte prolifera-
tion. Cell Mol Biol Lett 2003;8:699–711.
29. Wang Y, Huang C, Cao Y, Han JS. Repeated administration of low
dose ketamine for the treatment of monoarthritic pain in the rat.
Life Sci 2000;67:261–7.
30. Laird JM, Carter AJ, Grauert M, Cervero F. Analgesic activity
of a novel use-dependent sodium channel blocker, crobenetine,
in mono-arthritic rats. Br J Pharmacol 2001;134:1742–8.
31. Yu YC, Koo ST, Kim CH, Lyu Y, Grady JJ, Chung JM.
Two variables that can be used as pain indices in experimental
animal models of arthritis. J Neurosci Methods 2002;115:107–13.
32. Whitehouse MW. Adjuvant-induced polyarthritis in rats.
In: Greenwald RA, Diamond HS (eds). CRC Handbook of Animal
Models for the Rheumatic Diseases, Vol. 1, Miami, FL, USA: CRC
Press, 1996.
33. Beilin B, Bessler H, Mayburd E, Smirnov G, Dekel A, Yardeni I,
et al. Effects of preemptive analgesia on pain and cytokine produc-
tion in the postoperative period. Anesthesiology 2003;98:151–5.
34. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J,
O’Connor K, et al. Controlling pathological pain by adenovirally
driven spinal production of the anti-inflammatory cytokine,
interleukin-10. Eur J Neurosci 2005;21:2136–48.
35. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE,
Nickerson P, et al. Cytokine genotypes correlate with
pain and radiologically defined joint damage in patients with
juvenile rheumatoid arthritis. Rheumatology (Oxford)
2005;44:1115–21.
36. Wu CT, Jao SW, Borel CO, Yeh CC, Li CY, Lu CH, et al. The
effect of epidural clonidine on perioperative cytokine response,
postoperative pain, and bowel function in patients undergoing
colorectal surgery. Anesth Analg 2004;99:502–9.
37. Sommer C. Animal studies on neuropathic pain: the role of
cytokines and cytokine receptors in pathogenesis and therapy.
Schmerz 1999;13:315–23.
38. Kwon MS, Shim EJ, Seo YJ, Choi SS, Lee JY, Lee HK, et al.
Effect of aspirin and acetaminophen on pro-inflammatory
cytokine-induced pain behavior in mice. Pharmacology
2005;74:152–156.
Received November 9, 2006; accepted July 10, 2007
eCAM 2009;6(2) 245
